BEIJING – Friedhelm Blobel, CEO and president of Sciclone, knows about running a specialty pharmaceutical company in China. His company, based in Foster City, Calif., and listed on Nasdaq, has a 17-year track record in China selling its $100 million-a-year drug Zadaxin.